EP2591359A4 - METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES - Google Patents

METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES

Info

Publication number
EP2591359A4
EP2591359A4 EP11804372.8A EP11804372A EP2591359A4 EP 2591359 A4 EP2591359 A4 EP 2591359A4 EP 11804372 A EP11804372 A EP 11804372A EP 2591359 A4 EP2591359 A4 EP 2591359A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
quantifying exosomes
exosomes
quantifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11804372.8A
Other languages
German (de)
French (fr)
Other versions
EP2591359A2 (en
EP2591359B1 (en
Inventor
Richard H Tullis
Paul Duffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aethlon Medical Inc
Original Assignee
Aethlon Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aethlon Medical Inc filed Critical Aethlon Medical Inc
Publication of EP2591359A2 publication Critical patent/EP2591359A2/en
Publication of EP2591359A4 publication Critical patent/EP2591359A4/en
Application granted granted Critical
Publication of EP2591359B1 publication Critical patent/EP2591359B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP11804372.8A 2010-07-07 2011-07-07 Methods for quantifying exosomes Active EP2591359B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36212910P 2010-07-07 2010-07-07
PCT/US2011/043265 WO2012006476A2 (en) 2010-07-07 2011-07-07 Methods and compositions for quantifying exosomes

Publications (3)

Publication Number Publication Date
EP2591359A2 EP2591359A2 (en) 2013-05-15
EP2591359A4 true EP2591359A4 (en) 2014-01-22
EP2591359B1 EP2591359B1 (en) 2017-03-01

Family

ID=45441811

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11804372.8A Active EP2591359B1 (en) 2010-07-07 2011-07-07 Methods for quantifying exosomes

Country Status (4)

Country Link
US (2) US20130323756A1 (en)
EP (1) EP2591359B1 (en)
ES (1) ES2624284T3 (en)
WO (1) WO2012006476A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116362A2 (en) 2005-04-25 2006-11-02 The Trustees Of Boston University Structured substrates for optical surface profiling
CA3061952C (en) * 2006-03-09 2022-07-19 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US9493810B2 (en) * 2012-06-07 2016-11-15 Pioma, Inc. 5-ALA for detection of brain tumors
KR101933622B1 (en) * 2012-10-09 2018-12-28 삼성전자주식회사 Compositions for monitoring a vesicle, kits and methods for monitoring the vesicle using the same
WO2014059336A1 (en) 2012-10-12 2014-04-17 University Of Notre Dame Du Lac Exosomes and diagnostic biomarkers
CN103767985A (en) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 Preparation and application of exosome secreted by human derived blood or mesenchymal stem cell
EP2941629B1 (en) * 2013-01-03 2018-10-10 Exosome Diagnostics Inc. Methods for isolating microvesicles
CA2904181A1 (en) 2013-03-13 2014-10-09 Anahit Aghvanyan Sandwich immunoassay comprising anchoring reagent
US10114015B2 (en) 2013-03-13 2018-10-30 Meso Scale Technologies, Llc. Assay methods
WO2014167969A1 (en) * 2013-04-08 2014-10-16 塩野義製薬株式会社 Method for detecting colon cancer
WO2015143113A1 (en) * 2014-03-20 2015-09-24 Barb Ariel Cohen Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations
WO2015175856A1 (en) 2014-05-15 2015-11-19 Meso Scale Technologies, Llc. Improved assay methods
US11268085B2 (en) 2014-05-27 2022-03-08 Exosome Diagnostics, Inc. Methods for isolating microvesicles and extracting nucleic acids from biological samples
KR102596577B1 (en) 2014-07-09 2023-10-30 엑소좀 디아그노스틱스, 인크. Methods for isolating microvesicles and extracting nucleic acids from biological samples
JP2016147839A (en) * 2015-02-13 2016-08-18 国立大学法人広島大学 Protein isolation device, protein isolation method, and method for determining high mannose type sugar chain structure
WO2016201064A1 (en) 2015-06-09 2016-12-15 The Board Of Regents Of The University Of Texas System Diagnostic test for early stage cancer
CN114217058A (en) 2015-09-22 2022-03-22 波士顿大学董事会 Multiplex phenotypic analysis of nanovesicles
JP7033082B2 (en) 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド Detection of exosomes with surface markers
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
JP7081763B2 (en) 2017-05-12 2022-06-07 国立大学法人広島大学 Cancer diagnostic device
KR102243415B1 (en) * 2017-09-27 2021-04-22 ㈜로제타엑소좀 Method for the analysis of extracellular vesicles using size exclusion chromatography and use thereof
WO2019066501A1 (en) * 2017-09-27 2019-04-04 ㈜로제타엑소좀 Analysis method for extracellular vesicles, using size exclusion chromatography, and use for same
CN109490528A (en) * 2017-10-05 2019-03-19 香港科技大学 exosome analysis and cancer diagnosis method
US12083448B2 (en) 2017-12-29 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purification and labeling of extracellular vesicles using a mixed mode resin composition
JP2019154283A (en) * 2018-03-09 2019-09-19 国立大学法人京都大学 Methods for detecting osteoblasts in a cell population obtainable by inducing differentiation of pluripotent stem cells to osteoblasts
EP3803332A1 (en) 2018-06-01 2021-04-14 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
EP3867638B1 (en) * 2018-10-17 2024-12-04 Immutrix Therapeutics, Inc. Adsorption and binding of plasma molecules and particles to carbon
AU2020232954B2 (en) 2019-03-01 2026-01-15 Meso Scale Technologies, Llc. Electrochemiluminescent labeled probes for use in immunoassay methods, methods using such and kits comprising same
CN111257073B (en) * 2020-01-19 2022-03-25 北京尧景基因技术有限公司 Lectin-macromolecular carrier coupling compound for separating glycosylation exosomes in clinical sample
CN111253491B (en) * 2020-01-19 2022-03-25 北京尧景基因技术有限公司 Lectin-magnetic carrier coupled complex for separating glycosylated exosomes in clinical sample
JP7591205B2 (en) * 2020-09-01 2024-11-28 株式会社Ｊｖｃケンウッド Pancreatic cancer data collection method and pancreatic cancer detection kit
CN113275133A (en) * 2021-06-09 2021-08-20 会泽县民悦农业科技有限公司 Clean type unprocessed food grains edulcoration system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103572A2 (en) * 2006-03-09 2007-09-13 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
WO2009092386A2 (en) * 2008-01-25 2009-07-30 Hansabiomed Oü A new method to measure and characterize microvesicles in the human body fluids
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
WO2010141862A2 (en) * 2009-06-05 2010-12-09 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
WO2012170711A1 (en) * 2011-06-07 2012-12-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L Circulating biomarkers for cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629694A (en) * 1983-07-12 1986-12-16 Cornell Research Foundation, Inc. Detecting and distinguishing between plasminogen activators
WO1998016825A1 (en) * 1996-10-15 1998-04-23 Seikagaku Corporation METHOD FOR ASSAYING AGALACTO-IgG AND ASSAY KITS, POLYPEPTIDES OF LECTINS, AND DNAS ENCODING THE SAME
FR2788780B1 (en) 1999-01-27 2001-03-30 Ap Cells Inc PROCESS FOR THE PREPARATION OF MEMBRANE VESICLES
KR100394940B1 (en) * 1999-11-10 2003-08-19 주식회사 코비아스 Method for measuring serum asialo-glycoprotein concentration for diagnosis of hepatic disease and a kit therefor
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
AU2001252945A1 (en) * 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
US7462491B2 (en) * 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
CN101124315A (en) 2003-01-17 2008-02-13 伊势龙医学股份有限公司 Method for removing virus in blood by using lectin-affinity hemodialysis
ES2743543T3 (en) * 2005-05-05 2020-02-19 Univ Drexel Diagnosis of liver pathology through the evaluation of fucosylated quininogen
US8105839B2 (en) * 2006-09-06 2012-01-31 National University Corporation Tottori University Diagnostic kit for Alzheimer's disease, diagnostic marker, and detection method for indicator of pathological state thereof
WO2009015357A1 (en) * 2007-07-25 2009-01-29 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103572A2 (en) * 2006-03-09 2007-09-13 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
WO2009092386A2 (en) * 2008-01-25 2009-07-30 Hansabiomed Oü A new method to measure and characterize microvesicles in the human body fluids
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2010065765A2 (en) * 2008-12-04 2010-06-10 Aethlon Medical, Inc. Affinity capture of circulating biomarkers
WO2010141862A2 (en) * 2009-06-05 2010-12-09 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
WO2012170711A1 (en) * 2011-06-07 2012-12-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L Circulating biomarkers for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOTHERAPY, vol. 35, no. 9, November 2012 (2012-11-01), 27TH ANNUAL SCIENTIFIC MEETING OF THE SOCIETY-FOR-IMMUNOTHERAPY-OF-CANCER (SITC); NORTH BETHESDA, MD, USA; OCTOBER 24 -28, 2012, pages 778 - 779, XP008166223 *
See also references of WO2012006476A2 *

Also Published As

Publication number Publication date
US20200166514A1 (en) 2020-05-28
EP2591359A2 (en) 2013-05-15
WO2012006476A3 (en) 2012-04-12
ES2624284T3 (en) 2017-07-13
WO2012006476A2 (en) 2012-01-12
EP2591359B1 (en) 2017-03-01
US20130323756A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
EP2591359A4 (en) METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES
EP2742154A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2721179A4 (en) BIOMARKER COMPOSITIONS AND ASSOCIATED METHODS
EP2544679A4 (en) PDE10 INHIBITORS AND ASSOCIATED COMPOSITIONS AND METHODS
EP2922861A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2611496A4 (en) PROCESSING METHODS
ES2953308T5 (en) Compositions and methods for analyte detection
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND ASSOCIATED METHODS
EP2761065A4 (en) COMPOSITIONS AND METHODS FOR PERFORMING TOXIGENICITY TESTS
EP2665521A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2207424A4 (en) COMPOSITIONS AND METHODS FOR TREATING PURPURA
EP2473034A4 (en) COMPOSITIONS AND METHODS FOR TREATING SEEDS
IL231131A0 (en) Methods and compositions for determining smoking status
EP2971280A4 (en) COMPOSITIONS AND METHODS FOR MICROARRAYS OF BIOSENSORS
EP2635254A4 (en) COMPOSITIONS AND METHODS FOR REDUCING MUCOADHÉRENCE
EP2750495A4 (en) METHODS AND COMPOSITIONS FOR FERTILIZING PASCALIES
IL233023A0 (en) Methods and systems for using exosomes to determine pamotypes
EP2547795A4 (en) COMPOSITIONS AND METHODS FOR SEARCHING GENOMIC CHARACTERISTICS
EP2608767A4 (en) POLYMER COMPOSITIONS AND ASSOCIATED METHODS
EP2934181A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING SOLUBILITY OF REBAUDIOSIDE X
EP2536293A4 (en) METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE
EP2914084A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING PLANT DEVELOPMENT
EP2931324A4 (en) COMPOSITIONS AND METHODS FOR TISSUE REGENERATION
EP2542187A4 (en) DEVICES AND METHODS FOR REGENERATING BONE DEFECTS
EP2858648A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING PIN1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20131220

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101AFI20131216BHEP

Ipc: C12Q 1/06 20060101ALI20131216BHEP

Ipc: G01N 33/58 20060101ALI20131216BHEP

17Q First examination report despatched

Effective date: 20150430

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160509

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

INTC Intention to grant announced (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AETHLON MEDICAL INC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160928

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 871963

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011035500

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170301

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2624284

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170713

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 871963

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170601

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170602

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170601

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170701

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170703

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011035500

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

26N No opposition filed

Effective date: 20171204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170707

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170731

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110707

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230501

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250529

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250610

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250806

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250604

Year of fee payment: 15